N a novel class of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent versions. J Pharmacol Exp Ther 2008, 327:26876. 28. Sigafoos J, Bowers G, Castellino S, Culp AG, Wagner DS, Reese JM, Humphreys JE, Hussey EK, O’Connor-Semmes RL, Kapur A, Tao W, Dobbins RL, Polli JW: Evaluation of the drug interaction chance for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: proof from in vitro, human mass stability, and ketoconazole interaction scientific studies. Drug Metab Dispos 2012, forty:2090101. 29. Dobbins R, Kapur A, Kapitza C, O’Connor-Semmes R, Tao W, Hussey E: Remogliflozin etabonate, a selective inhibitor with the sodium-glucose transporter 2 (SCLT2) decreases serum glucose in type 2 diabetes mellitus (T2DM) individuals. Diabetes 2009, 58:1573-P. thirty. Kapur A, O’Connor-Semmes R, Hussey E, Dobbins R, Tao W, Hompesch M, Nunez D: To start with human dose escalation examine with remogliflozin etabonate (RE) in healthful topics and in subjects with style 2 diabetes mellitus (T2DM).Neurotrophin-3 Protein, Human Diabetes 2009, 58:509-P.Gimeracil 31. Sung EY, Moore MP, Lunt H, Doogue M, Zhang M, Begg EJ: Do thiazide diuretics alter the pharmacokinetics of metformin in patients with sort 2 diabetes already established on metformin Br J Clin Pharmacol 2009, 67:13031. 32. Thurman J, Wiseman A: The patient with glomerulonephritis or vasculitis. In Guide of Nephrology. 7th edition. Edited by Schrier RW. Philadelphia: Lippincott Williams Wilkins; 2009:14053. 33. Saffar F, Aiache JM, Andre P: Influence of foods within the disposition with the antidiabetic drug metformin in diabetic sufferers at steady-state. Solutions Locate Exp Clin Pharmacol 1995, 17:48387. 34. Timmins P, Donahue S, Meeker J, Marathe P: Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005, 44:72129. 35. Schuirmann DJ: A comparison in the two one-sided tests procedure as well as energy technique for assessing the equivalence of common bioavailability. J Pharmacokinet Biopharm 1987, 15:65780. 36. Hauschke D, Steinijans VW, Diletti E: A distribution-free process to the statistical examination of bioequivalence scientific studies. Int J Clin Pharmacol Ther Toxicol 1990, 28:728. 37. Hollander M, Wolfe DA: Nonparametric Statistical Techniques. Ny: Wiley; 1973. 38. Del Prato S, Felton A-M, Munro N, Nesto R, Zimmet P, Zinman B, on behalf of the Global Partnership for Productive Diabetes Management: Improving glucose management: ten techniques to have a lot more individuals with variety two diabetes to intention. Suggestions in the Worldwide Partnership for Effective Diabetes Management. Int J Clin Pract 2005, 59:1345355. 39. Polli JW, Humphreys JE, Harmon KA, Webster LO, Reese MJ, MacLauchlin CC: Assessment of remogliflozin etabonate, a sodium-dependent glucose co-transporter-2 inhibitor, being a perpetrator of clinical drug interactions: a examine on drug transporters and metabolic enzymes.PMID:24025603 J Diabetes Metab 2012, three:five. http://dx.doi.org/10.4172/2155-6156.1000200.doi:ten.1186/2050-6511-14-25 Cite this article as: Hussey et al.: Security, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type two diabetes mellitus. BMC Pharmacology and Toxicology 2013 14:25.
The Journal of Neuroscience,February1, 1996,76(3):1066-iThe Possible EndogenousKazuhoRole of Hydrogen NeuromodulatorKimuraSulfideas anAbe and HideoThe Salk Institute for Biological Studies, San Diego, California 92Hydrogen sulf.
